PT  - JOURNAL ARTICLE
AU  - Lu, Fang-Lin
AU  - An, Zhao
AU  - Ma, Ye
AU  - Song, Zhi-Gang
AU  - Cai, Cheng-Liang
AU  - Li, Bai-Ling
AU  - Zhou, Guang-Wei
AU  - Han, Lin
AU  - Wang, Jun
AU  - Bai, Yi-Fan
AU  - Liu, Xiao-Hong
AU  - Wang, Jia-Feng
AU  - Meng, Xu
AU  - Zhang, Hai-Bo
AU  - Yang, Jian
AU  - Dong, Nian-Guo
AU  - Hu, Sheng-Shou
AU  - Pan, Xiang-Bin
AU  - Cheung, Anson
AU  - Qiao, Fan
AU  - Xu, Zhi-Yun
TI  - Transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation
AID  - 10.1136/heartjnl-2020-318199
DP  - 2021 Oct 01
TA  - Heart
PG  - 1664--1670
VI  - 107
IP  - 20
4099  - http://heart.bmj.com/content/107/20/1664.short
4100  - http://heart.bmj.com/content/107/20/1664.full
SO  - Heart2021 Oct 01; 107
AB  - Objective Tricuspid regurgitation (TR) is a common valvular heart disease with unsatisfactory medical therapeutics and high surgical mortality. The present study aims to evaluate the safety and effectiveness of transcatheter tricuspid valve replacement (TTVR) in high-risk patients with severe TR.Methods This was a compassionate multicentre study. Between September 2018 and November 2019, 46 patients with TR who were not suitable for surgery received compassionate TTVR under general anaesthesia and the guidance of trans-oesophageal echocardiography and fluoroscopy in four institutions. Access to the tricuspid valve was obtained via a minimally invasive thoracotomy and transatrial approach. Patients’ data at baseline, before discharge, 30 days and 6 months after the procedure were collected.Results All patients had severe TR with vena contracta width of 12.6 (11.0, 14.5) mm. Procedural success (97.8%) was achieved in all but one case with right ventricle perforation. The procedural time was 150.0 (118.8, 180.0) min. Intensive care unit time was 2.0 (1.0, 4.0) days. 6-month mortality was 17.4%. Device migration occurred in one patient (2.4%) during follow-up. Transthoracic echocardiography at 6 months after operation showed TR was significantly reduced (none/trivial in 33, mild in 4 and moderate in 1) and the primary safety end point was achieved in 38 cases (82.6%). Patients suffered from peripheral oedema and ascites decreased from 100.0% and 47.8% at baseline to 2.6% and 0.0% at 6 months.Conclusions The present study showed TTVR was feasible, safe and with low complication rates in patients with severe TR.All data relevant to the study are included in the article or uploaded as supplementary information.